TLPPF · Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited disclosed the settlement of US$600 million convertible bonds through an announcement to the Australian Securities Exchange on April 23, 2026 (Melbourne time), with the press release attached as Exhibit 99.1. This event represents a significant financing milestone for the company, likely resolving outstanding convertible debt obligations and impacting its capital structure. The timing, just one day after the Form 6-K filing date of April 22, 2026, underscores the materiality for investors tracking debt maturities and liquidity. Settlement of convertible bonds can reduce dilution risk if conversion features are exercised or redeemed, providing clarity on the company's balance sheet post-transaction. The document, signed by Group General Counsel Christian Krautkramer, ensures regulatory compliance for the foreign private issuer. Investors should review Exhibit 99.1 for specifics on settlement terms, conversion ratios, redemption details, and any associated cash outflows or equity impacts, as these directly affect future financial flexibility and shareholder value.